Lymphopenia and Early Variation of Lymphocytes to Predict In-Hospital Mortality and Severity in ED Patients with SARS-CoV-2 Infection.
Maxence SimonPierrick Le BorgneFrançois LefevbreSylvie ChabrierLauriane CipolatAline RemillonFlorent BaicryPascal BilbaultCharles-Eric LavoignetLaure Abensur VuillaumePublished in: Journal of clinical medicine (2022)
(1) Introduction: Multiple studies have demonstrated that lymphocyte count monitoring is a valuable prognostic tool for clinicians during inflammation. The aim of our study was to determine the prognostic value of delta lymphocyte H24 from admission from the emergency department for mortality and severity of SARS-CoV-2 infection. (2) Methods: We have made a retrospective and multicentric study in six major hospitals of northeastern France. The patients were hospitalized and had a confirmed diagnosis of SARS-CoV-2 infection. (3): Results: A total of 1035 patients were included in this study. Factors associated with infection severity were CRP > 100 mg/L (OR: 2.51, CI 95%: (1.40-3.71), p < 0.001) and lymphopenia < 800/mm 3 (OR: 2.15, CI 95%: (1.42-3.27), p < 0.001). In multivariate analysis, delta lymphocytes H24 (i.e., the difference between lymphocytes values at H24 and upon admission to the ED) < 135 was one of the most significant biochemical factors associated with mortality (OR: 2.23, CI 95%: (1.23-4.05), p = 0.009). The most accurate threshold for delta lymphocytes H24 was 75 to predict severity and 135 for mortality. (4) Conclusion: Delta lymphocytes H24 could be a helpful early screening prognostic biomarker to predict severity and mortality associated with COVID-19.
Keyphrases
- emergency department
- peripheral blood
- end stage renal disease
- cardiovascular events
- ejection fraction
- newly diagnosed
- chronic kidney disease
- oxidative stress
- risk factors
- coronavirus disease
- sars cov
- prognostic factors
- peritoneal dialysis
- cardiovascular disease
- palliative care
- mass spectrometry
- adverse drug
- case control
- drug induced
- water quality